Team TrEE
Phone: 04 76 63 74 73
Address: Bâtiment Jean Roget, Place du Commandant Nal, Domaine de la Merci
Office: 820

Dr Audrey Le Gouellec is an Associate Professor and Hospital Practitioner in clinical biochemistry at the Faculty of Medicine, Université Grenoble Alpes (UGA) and Centre Hospitalier Universitaire de Grenoble Alpes (CHUGA). She is the scientific manager of the GExiM Mass Spectrometry Metabolomics platform. Recruited since 2016, she focuses her research in the TIMC laboratory (UMR 5525 CNRS-UGA) on the study of host-pathogen interaction and considers each time medical applications. At CHUGA, within the Biochemistry, Molecular Biology and Environmental Toxicology department, Audrey Le Gouellec is a biologist, responsible for 36 clinical parameters of routine biochemistry care such as inflammation and CSF markers. She is president of the “Reseau Francophone de Metabolomique et Fluxomique (RFMF) and deputy director of the graduate school (Ingenierie de la Santé de la Cognition et de l'Environenement).” She published 44 peer-reviewed articles (h-index: 19, num. of citations: 1808, SIGAPS: 444).


  • Biochemistry 
  • Metabolomics 
  • Synthetic biology 
  • Biotechnology 
  • Live biotherapeutic
  • Pseudomonas aeruginosa
Supervised thesis
Alexandre TRONEL : "Caractérisation du microbiome de l’intestin grêle humain via analyses multi-omiques et optimisation d’un dispositif médical de prélèvement in-situ non invasif."
Charles TERRA : "Impact de l'infection virale à SARS-Cov2 sur le métabolisme des cellules de l'épithélium pulmonaire"

1. Pernot, L., Chesnel, L., Le Gouellec, A., Croize, J., Vernet, T., Dideberg, O., & Dessen, A. (2004). A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism for reduction of susceptibility to beta-lactam antibiotics. Journal of Biological Chemistry, 279(16), 16463–16470. (SIGAPS B, IF 6,35)

2. Noirclerc-Savoye, M., Le Gouellec, A., Morlot, C., Dideberg, O., Vernet, T., & Zapun, A. (2005). In vitro reconstitution of a trimeric complex of DivIB, DivIC and FtsL, and their transient co-localization at the division site in Streptococcus pneumoniae. Molecular Microbiology, 55(2), 413–424. (SIGAPS B, IF 6,2)

3. Morlot, C., Pernot, L., Le Gouellec, A., Di Guilmi, A. M., Vernet, T., Dideberg, O., & Dessen, A. (2005). Crystal structure of apeptidoglycan synthesis regulatory factor (PBP3) from Streptococcus pneumoniae. Journal of Biological Chemistry,
280(16), 15984–15991. (SIGAPS B, IF 5,85)

4. Le Gouellec, A., Roux, L., Fadda, D., Massidda, O., Vernet, T., & Zapun, A. (2008). Roles of pneumococcal DivIB in cell division. Journal of Bacteriology, 190(13), 4501–4511. (SIGAPS B, IF 3,63)

5. Masson, S., Kern, T., Le Gouellec, A., Giustini, C., Simorre, J. P., Callow, P., … Zapun, A. (2009). Central Domain of DivIB Caps the C-terminal Regions of the FtsL/DivIC Coiled-coil Rod. Journal of Biological Chemistry, 284(40), 27687–27700. (SIGAPS B, IF 5,32)

6. Derouazi, M., Wang, Y., Marlu, R., Epaulard, O., Mayol, J-F., Pasqual, N., Le Gouellec, A., Polack, B. and Toussaint, B., “Optimal epitope composition after antigen screening using a live bacterial delivery vector Application to TRP-2,” Bioeng.
Bugs, vol. 1, no. 1, pp. 51–60, 2010.

7. Le Gouellec, A., Chauchet, X., Polack, B., Buffat, L., & Toussaint, B. (2012). Bacterial vectors for active immunotherapy
reach clinical and industrial stages. Human Vaccines & Immunotherapeutics, 8(10), 1454–1458. (SIGAPS D, IF 2,1)

8. Wang, Y., Le Gouellec, A., Chaker, H., Asrih, H., Polack, B., & Toussaint, B. (2012). Optimization of Antitumor Immunotherapy Mediated by Type III Secretion System-based Live Attenuated Bacterial Vectors. Journal of Immunotherapy, 35(3), 223–234. (SIGAPS C, IF 3,46) 

9. Le Gouellec, A., Polack, B., & Toussaint, B. (2012). Regulation of the expression of type 3 secretion system : an exemple
from P. aeruginosa. Regulation of Bacterial Virulence. Book ASM

10. Le Gouëllec A, Chauchet X, Laurin D, Aspord C, Verove J, Wang Y, Genestet C, Trocme C, Ahmadi M, Martin S, Broisat A, Cretin F, Ghezzi C, Polack B, Plumas J, Toussaint B. A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy Mol Ther. 2013 May;21(5):1076-86. (SIGAPS A IF 6,42) 

11. Polack B. Berthoin L., Le Gouellec A., Lenormand J.-L., Toussaint B. ,Garban F., L. D. (2013). IPS sécurisées : perspectives pour la thérapie cellulaire. Transfusion Clinique et Biologique.

12. Toussaint, B., Chauchet, X., Wang, Y., Polack, B., & Le Gouëllec, A. (2013). Live-attenuated bacteria as a cancer vaccine
vector. Expert Rev Vaccines, 12(10), 1139–1154. (SIGAPS B, IF 4,2)

13. Wang, Y., Toussaint, B., & Le Gouellec, A. (2014). Bacterial vectors for the delivery of tumor antigens. Methods in Molecular Biology (Clifton, N.J.), 1139, 429–441. (SIGAPS NC)

14. Genestet, C., Le Gouellec, A., Chaker, H., Polack, B., Guery, B., Toussaint, B., & Stasia, M. J. (2014). Scavenging of reactive oxygen species by tryptophan metabolites helps Pseudomonas aeruginosa escape neutrophil killing. Free Radical Biology and Medicine, 73, 400–410. (SIGAPS B, IF 5,7) 

15. Boulet, L., Flore, P., Le Gouellec, A., Toussaint, B., Pepin, J. L., & Faure, P. (2015). Is tryptophan metabolism involved in
sleep apnea-related cardiovascular co-morbidities and cancer progression? Med Hypotheses, 85(4), 415–423. (SIGAPS E, IF 1,1)

16. Chauchet, X., Hannani, D., Djebali, S., Laurin, D., Polack, B., Marvel, J., … Le Gouellec, A. (2016). Poly-functional and longlasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery. Mol Ther Oncolytics, 3, 16033. (SIGAPS E, IF 1,25) 

17. Bortolotti, P., Hennart, B., Thieffry, C., Jausions, G., Faure, E., Grandjean, T., … Le Gouellec, A. (2016). Tryptophan catabolism in Pseudomonas aeruginosa and potential for inter-kingdom relationship. BMC Microbiol, 16(1), 137. (SIGAPS C, IF 2,64) 

18. Berthoin, L., Toussaint, B., Garban, F., Le Gouellec, A., Caulier, B., Polack, B., & Laurin, D. (2016). Targeted release of transcription factors for cell reprogramming by a natural micro-syringe. Int J Pharm, 513(1–2), 678–687. (SIGAPS B, IF 3,65)

19. Richard, E., Pifferi, C., Fiore, M., Samain, E., Le Gouellec, A., Fort, S., … Priem, B. (2017). Chemobacterial Synthesis of a Sialyl-Tn Cyclopeptide Vaccine Candidate. Chembiochem, 18(17), 1730–1734. (SIGAPS D, IF 2,77)

20. Le Gouellec, A., Toussaint, B., & Park, S. (2017). Cibler les mécanismes immunosuppresseurs de la réponse immune antitumorale en onco-hématologie : une nouvelle stratégie thérapeutique ? Immune checkpoint blockade in oncohematology therapy. Innovations et Thérapeutiques En Oncologie, 3 (Numéro 2). (SIGAPS NC) 

21. Meynet, E., Laurin, D., Lenormand, J. L., Camara, B., Toussaint, B., & Le Gouellec, A. (2018). Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonasaeruginosa pulmonary infections. Vaccine, 36(14), 1893–1900. (SIGAPS C, IF 3,27) 

22. Cachat, J., Deffert, C., Alessandrini, M., Roux-Lombard, P., Le Gouellec, A., Stasia, M. J., … Krause, K. H. (2018). Altered Humoral Immune Responses and IgG Subtypes in NOX2-Deficient Mice and Patients: A Key Role for NOX2 in Antigen- Presenting Cells. Front Immunol, 9, 1555. (SIGAPS C, IF 4,71)

23. Le Gouellec, A., Moyne, O., Meynet, E., Toussaint, B., & Fauvelle, F. (2018). HR-MAS NMR-based metabolomics reveals
metabolic changes in lung of mice infected with P. aeruginosa consistent with the degree of disease severity, and is a powerful evaluation tool for new treatment. J Proteome Res. (SIGAPS B,
IF 3,78) 

24. Marlu, R., Malvezzi, P., Seyve, L., Jouve, T., Maurizi, J., Defendi, F., Le Gouellec, A. … Rostaing, L. (2018b). Effect of doublefiltration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation. Thromb
Res, 166, 113–121. (SIGAPS C, IF 3,26)

25. Marlu, R., Malvezzi, P., Seyve, L., Jouve, T., Maurizi, J., Defendi, F., Le Gouellec, A.… Rostaing, L. (2018a). Corrigendum to “Effect of double-filtration plasmapheresis for antibody-mediated rejection on hemostasis parameters and thrombin generation” [Thromb. Res. 166 (2018) 113-121]. Thromb Res, 171, 200.

26. Fuertes E., Carsin A.E., Garcia Larsen V., , Guerra S., Pin I., Leynaert B., Accordini S., Martinez-Moratalla J., M Anto J.,Urrutia I., Le Gouellec A., Heinrich J., Gislason T., Jõgi R., Janson C., Jarvis D., Garcia-Aymerich J., "Mediation analysis of
CRP on the association of physical activity with FEV1 and FVC: the ECRHS study." European Respiratory Journal 2018 52 : PA4483

27. Deloule V, Boisset C, Hannani D, Suau A, Le Gouellec A, Chroboczek J, Botté C, Yamaryo Y, Chirat C, “Prebiotic role of softwood hemicellulose in healthy mice model,” J. Funct. Foods, vol. 64, 2020. (SIGAPS NC)

28. Fuertes E, Carsin AE, Garcia-Larsen V, Guerra S, Pin I, Leynaert B, Accordini S, Martinez-Moratalla J, Antó JM, Urrutia I, LeGouellec A, Heinrich J, Gislason T, Jõgi R, Janson C, Jarvis D, Garcia-Aymerich J. The role of C-reactive protein levels on the association of physical activity with lung function in adults. PLoS One. 2019 Sep 23;14(9 (SIGAPS C, IF 2,74)

29. Jarmusch, Alan K., Mingxun Wang, Christine M. Aceves, Rohit S. Advani, Shaden Aguirre, Alexander A. Aksenov, GajenderAleti,…, Le Gouellec A,…, P. Dorrestein. “ReDU: A Framework to Find and Reanalyze Public Mass Spectrometry Data.” Nature Methods, 2020 August, 1–4. (SIGAPS A, IF 30,82)

30. Nothias, Louis-Félix, Daniel Petras, Robin Schmid, Kai Dührkop, Johannes Rainer, Abinesh Sarvepalli, Ivan Protsyuk,…, Le Gouellec A,…, P. Dorrestein. “Feature-Based Molecular Networking in the GNPS Analysis Environment.” Nature Methods,
2020 August, 1–4. (SIGAPS A, IF 30,82)

31. Méry G, Epaulard O, Borel AL, Toussaint B, Le Gouellec A. COVID-19: Underlying Adipokine Storm and Angiotensin 1-7
Umbrella. Front Immunol. 2020 Jul 21;11:1714. doi: 10.3389/fimmu.2020.01714. PMID: 32793244; PMCID: PMC7385229.
(SIGAPS B, IF 5,085)

32. Moyne, O., Castelli, F., Bicout, D. J., Boccard, J., Camara, B., Cournoyer, B., … Le Gouëllec, A. (2021). Metabotypes of
pseudomonas aeruginosa correlate with antibiotic resistance, virulence and clinical outcome in cystic fibrosis chronic
infections. Metabolites, 11(2), 1–20. (SIGAPS C, IF 4,097) 

33. Schmid, R., Petras, D., Nothias, L. F., Wang, M., Aron, A. T., Jagels, A., …, Le Gouellec A., …,  Dorrestein, P. C. (2021). Ion identity molecular networking for mass spectrometry-based metabolomics in the GNPS environment. Nature Communications, 12(1).

34. Caffaratti, Clément, Caroline Plazy, Geoffroy Mery, Abdoul-Razak Tidjani, Federica Fiorini, Sarah Thiroux, Bertrand Toussaint, Dalil Hannani, and Audrey Le Gouellec. 2021. “What We Know So Far about the Metabolite-Mediated Microbiota-Intestinal Immunity Dialogue and How to Hear the Sound of This Crosstalk.” Metabolites 11 (6): 406.

35. Sannicolo, Sarah, Matteo Giaj Levra, Audrey Le Gouellec, Caroline Aspord, Julien Boccard, Laurence Chaperot, Bertrand Toussaint, Denis Moro-Sibilot, Dalil Hannani, and Anne-Claire Toffart. 2021. “Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: METABO-ICI Clinical Study Protocol.” Respiratory Medicine and Research, June, 100845.

36. Vanhaverbeke Cécile, Touboul David, Elie Nicolas, Prévost Martine, Meunier Cécile, Michelland Sylvie, Cunin Valérie, Ma Ling, Vermijlen David, Delporte Cédric, Pochet Stéphanie, Le Gouellec Audrey, Sève Michel, Van Antwerpen Pierre and Souard Florence (2021). Untargeted metabolomics approach to discriminate mistletoe commercial products. Scientific Reports, 11(1), 14205.

37. Federica Defendi, Corentin Leroy, Olivier Epaulard, Giovanna Clavarino, Antoine Vilotitch , Marion Le Marechal, Marie-Christine Jacob, Tatiana Raskovalova, Martine Pernollet, Audrey Le Gouellec, Jean-Luc Bosson, Pascal Poignard, Matthieu Roustit, Nicole Thielens, Chantal Dumestre-Perard1, and Jean-Yves Cesbron. 2021. Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality. Frontiers in Immunology, 12.

38. Clavarino, G.; Leroy, C.; Epaulard, O.; Raskovalova, T.; Vilotitch, A.; Pernollet, M.; DUMESTRE-PERARD, C.; Defendi, F.; Le Maréchal, M.; …,Le Gouellec, A.; …, Cesbron JY. Fine analysis of lymphocyte subpopulations in SARS-CoV-2 infected patients: differential profiling of patients with severe outcome. Front. Immunol. 2022, 0, 3154, doi:10.3389/FIMMU.2022.889813.

39.Guillon, A.; Brea-Diakite, D.; Cezard, A.; Wacquiez, A.; Baranek, T.; Bourgeais, J.; Picou, F.; Vasseur, V.; Meyer, L.; Chevalier, C.; …, Le Gouellec, A., …, Si Tahar M.. Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein. EMBO J. 2022, 41, doi:10.15252/embj.2021108306.

40. Reig S, Le Gouellec A, Bleves S. What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert? Front Cell Infect Microbiol. 2022 Jul 8;12:909731. doi: 10.3389/fcimb.2022.909731. eCollection 2022. PMID: 35880080